Trial · NCT00445549
Adverse events74
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 74
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Investigations | Vandetanib Treatment | 8 | 12 | 15 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Investigations | Vandetanib Treatment | 11 | 12 | 16 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Vandetanib Treatment | 9 | 12 | 14 |
| other | Alkaline phosphatase | Investigations | Vandetanib Treatment | 4 | 12 | 6 |
| other | Anorexia | Metabolism and nutrition disorders | Vandetanib Treatment | 5 | 12 | 5 |
| other | Bilirubin (hyperbilirubinemia) | Hepatobiliary disorders | Vandetanib Treatment | 3 | 12 | 8 |
| other | Burn | Injury, poisoning and procedural complications | Vandetanib Treatment | 1 | 12 | 1 |
| other | Calcium, serum-low (hypocalcemia) | Metabolism and nutrition disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Constipation | Gastrointestinal disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Creatinine | Investigations | Vandetanib Treatment | 2 | 12 | 3 |
| other | Dehydration | Metabolism and nutrition disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Dermatology/Skin - Other (Specify, __) | Skin and subcutaneous tissue disorders | Vandetanib Treatment | 3 | 12 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Vandetanib Treatment | 10 | 12 | 21 |
| other | Distension/bloating, abdominal | Gastrointestinal disorders | Vandetanib Treatment | 2 | 12 | 2 |
| other | Dry mouth/salivary gland (xerostomia) | Gastrointestinal disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Vandetanib Treatment | 2 | 12 | 2 |
| other | Dyspnea (shortness of breath) | Respiratory, thoracic and mediastinal disorders | Vandetanib Treatment | 2 | 12 | 4 |
| other | Edema: limb | General disorders | Vandetanib Treatment | 1 | 12 | 1 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Vandetanib Treatment | 6 | 12 | 6 |
| other | Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L) | General disorders | Vandetanib Treatment | 3 | 12 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00445549/events